ArticlePsychiatry and clinical psychopharmacology2025
Risperidone Augmentation in Antidepressant-Resistant Somatic Symptom Disorder.
Article in Psychiatry and clinical psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluating the Therapeutic Efficacy of rTMS Combined with Low-Dose Antipsychotic Medication in Somatic Symptom Disorder.Neuropsychiatric disease and treatment · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic somatic symptoms are hallmarks of somatic symptom disorder (SSD), characterized by notable disruptions in the day to day lives of affected patients. Risperidone is an effective augmenting agent for treatment-resistant major depressive and obsessive-compulsive disorders. Although various antidepressants have been used for the pharmacotherapy of SSDs, no guidelines have been formulated for treatment-resistant or severe SSDs. To date, the efficacy of risperidone augmentation for the treatment of antidepressant-resistant SSD has not been reported. Here, we report the case of a 68-year-old female patient with SSD and comorbid persistent depressive disorder. Upon admission, laboratory tests revealed no abnormalities except for a high triglyceride level. Psychosocial functioning and depressive symptoms were evaluated using the Global Assessment of Functioning and Beck Depression Inventory II. The severe and persistent symptoms of the patient were remarkably alleviated following low-dose risperidone augmentation with mirtazapine combined with desvenlafaxine. Furthermore, notable therapeutic effect of risperidone augmentation was observed following a significant reduction in the subjective distress of the patient and functional recovery within a short period. Our report suggests that early augmentation with risperidone facilitates the analgesic effect of serotonergic/noradrenergic antidepressants and contributes significantly to the rapid amelioration of SSD severity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.